Recent Press Releases

Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO(R) (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation

Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO(R) (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation...

Producers of High Quality, Low Cost Generic Medicines Organize, "Coalition of Affordable Care" is formed - U.S.-based India First Group to Lead the Charge

Producers of High Quality, Low Cost Generic Medicines Organize, "Coalition of Affordable Care" is formed - U.S.-based India First Group to Lead the Charge WASHINGTON, Jun 25, 2014 (BUSINESS...

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

First biosimilar insulin to receive CHMP positive opinion in the EU

INDIANAPOLIS and INGELHEIM, Germany<

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

First biosimilar insulin to receive CHMP positive opinion in the EU

INDIANAPOLIS and RIDGEFIELD, Conn.,

Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations

-In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D...

Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

PRINCETON, N.J. & NEW YORK, Jun 27, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.74% and Pfizer Inc. PFE -0.14% today announced that the Committee for Medicinal Products for...

Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations

Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating...

CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer

CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer Avastin...

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ --...

Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C

Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C If Approved, Sofosbuvir Would Be the First All-Oral Treatment...

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ --...

Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation

Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation Idarucizumab being evaluated to specifically reverse...

Diabetes Scholars Foundation Announces 2014 Scholarship Recipients

Lilly Diabetes grants $200,000 for scholarships

ROLLING MEADOWS, Ill. and INDIANAPOLIS,

Abbott Hosts Conference Call for Second-Quarter Earnings

ABBOTT PARK, Ill., June 25, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2014 financial results on

Sinai Hospital Doctor's Research Shows Positive Long-term Outcomes of Medical Therapy for Cushing's Syndrome, a Devastating Rare Disease

Sinai Hospital Doctor's Research Shows Positive Long-term Outcomes of Medical Therapy for Cushing's Syndrome, a Devastating Rare Disease New study shows patients experienced significant, sustained...

Vyvanse(R) Patents Found to Be Infringed and Valid by U.S. District Court

LEXINGTON, Massachusetts, Jun 25, 2014 (PR Newswire Europe via COMTEX) -- LEXINGTON, Massachusetts, June 25, 2014 /PRNewswire/ -- Shire plc announces that Judge Stanley R. Chesler of the U.S....

AbbVie Inc. Statement regarding a possible offer for Shire plc

AbbVie Inc. Statement regarding a possible offer for Shire plc 25 June 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY...

Abbott Receives CE Mark for TECNIS® Symfony Extended Range of Vision Intraocular Lens for Cataract Patients

ABBOTT PARK, Ill., June 24, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in

Verizon Expands Access to Medical Care for Patients, With 'Verizon Virtual Visits'

New Mobile Health Product Allows Patients With Acute Conditions to See Clinicians via Smartphone, Tablet or Computer

NEW YORK,